DE3854741T2 - TREATING AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS. - Google Patents

TREATING AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS.

Info

Publication number
DE3854741T2
DE3854741T2 DE3854741T DE3854741T DE3854741T2 DE 3854741 T2 DE3854741 T2 DE 3854741T2 DE 3854741 T DE3854741 T DE 3854741T DE 3854741 T DE3854741 T DE 3854741T DE 3854741 T2 DE3854741 T2 DE 3854741T2
Authority
DE
Germany
Prior art keywords
autoantigens
oral administration
autoimmune diseases
treating autoimmune
autoimmune disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3854741T
Other languages
German (de)
Other versions
DE3854741D1 (en
DE3854741T3 (en
Inventor
Howard L Weiner
David A Hafler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autoimmune Inc
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22064733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3854741(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of DE3854741D1 publication Critical patent/DE3854741D1/en
Publication of DE3854741T2 publication Critical patent/DE3854741T2/en
Application granted granted Critical
Publication of DE3854741T3 publication Critical patent/DE3854741T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal

Abstract

The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral or enteral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease The method of the invention includes both prophylactic and therapeutic measures.
DE3854741T 1987-06-24 1988-06-24 TREATING AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS. Expired - Lifetime DE3854741T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6573487A 1987-06-24 1987-06-24
PCT/US1988/002139 WO1988010120A1 (en) 1987-06-24 1988-06-24 Treatment of autoimmune diseases by oral administration of autoantigens

Publications (3)

Publication Number Publication Date
DE3854741D1 DE3854741D1 (en) 1996-01-11
DE3854741T2 true DE3854741T2 (en) 1996-04-18
DE3854741T3 DE3854741T3 (en) 2002-08-14

Family

ID=22064733

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3854741T Expired - Lifetime DE3854741T3 (en) 1987-06-24 1988-06-24 TREATING AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS.
DE3856566T Expired - Lifetime DE3856566T2 (en) 1987-06-24 1988-06-24 Treatment of autoimmune diseases by oral administration of autoantigens

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE3856566T Expired - Lifetime DE3856566T2 (en) 1987-06-24 1988-06-24 Treatment of autoimmune diseases by oral administration of autoantigens

Country Status (8)

Country Link
EP (2) EP0359783B2 (en)
JP (1) JP2512796B2 (en)
AT (2) ATE258065T1 (en)
AU (1) AU632991B2 (en)
CA (1) CA1336954C (en)
DE (2) DE3854741T3 (en)
DK (1) DK175666B1 (en)
WO (1) WO1988010120A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
CA1340012C (en) * 1987-08-17 1998-08-25 Trustees Of Leland Stanford Jr. University Peptide determinant associated with immunity
DE68911653T2 (en) * 1988-11-03 1994-04-07 Schering Corp Antagonist for interleukin-5 to prevent or reduce eosinophilia.
NO306996B1 (en) * 1989-02-17 2000-01-24 Bayer Ag Isolated pancreatic cell (ICA) antigen for in vitro use
IL89431A0 (en) * 1989-02-27 1989-09-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of autoimmune diseases
CA2063416C (en) * 1989-07-14 2000-05-30 The United States Government Represented By The Secretary Of The Departm Ent Of Health And Human Services Methods of treating or preventing autoimmune uveoretinitis mammals
HUT61487A (en) * 1989-12-20 1993-01-28 Brigham & Womens Hospital Process for producing aerosol pharmaceutical composition comprising autoantigens
JPH06501464A (en) * 1990-09-28 1994-02-17 ブリティッシュ・テクノロジー・グループ・リミテッド antigen-antibody conjugate
US5620686A (en) * 1990-09-28 1997-04-15 British Technology Group Limited Antigen-antibody conjugates
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes
EP0553291B1 (en) * 1990-10-15 2006-03-08 Autoimmune, Inc. Treatment of autoimmune diseases by oral administration of autoantigens
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
AU674584B2 (en) * 1993-06-02 1997-01-02 Tvw Telethon Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
GB9319429D0 (en) 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
CA2203629A1 (en) * 1994-10-25 1996-05-02 Dawn Smilek Compositions and treatment for multiple sclerosis
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
BR9706922A (en) * 1996-01-05 1999-07-20 Autoimmune Inc Method to facilitate the removal of the pericondrial membrane from unprocessed vertebral cartilage tissue to remove proteoglycans from tissue containing type ii collagen and to obtain a product containing type ii collagen
KR20000070460A (en) * 1997-01-24 2000-11-25 왈리스 조 앤 Treatment of autoimmune disease using tolerization in combination with methotrexate
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
CA2315537A1 (en) 1997-12-16 1999-06-24 Regents Of The University Of Minnesota Methods to treat undesirable immune responses
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
ES2527760T3 (en) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
WO2001068124A2 (en) 2000-03-15 2001-09-20 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
DE60134862D1 (en) 2000-08-21 2008-08-28 Apitope Technology Bristol Ltd Tolerogenic peptides
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
ATE475883T1 (en) 2001-12-04 2010-08-15 Teva Pharma METHOD FOR MEASURING THE POWER OF GLATIRAMER ACETATE
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP2345421A1 (en) 2003-06-23 2011-07-20 Biotech Tools S.A. Epitope composition for sublingual or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989819A (en) * 1969-03-05 1976-11-02 American Cyanamid Company Process for separating proteins from central nervous system tissue and treating experimentally induced demyelinating diseases
US4350682A (en) † 1979-05-11 1982-09-21 Lescarden Ltd. Cartilage extraction processes and products
JP2633881B2 (en) † 1986-06-30 1997-07-23 マサチューセッツ インスティテュート オブ テクノロジー Immunomodulatory compositions and their use
CA1340012C (en) † 1987-08-17 1998-08-25 Trustees Of Leland Stanford Jr. University Peptide determinant associated with immunity
GB8803881D0 (en) * 1988-02-19 1988-03-23 Traqson Ltd Novel photoactive compounds processes for their production & intermediates thereof
AU3320089A (en) * 1988-04-20 1989-10-26 Hartech (Australia) Pty. Ltd. Portable traffic lights

Also Published As

Publication number Publication date
JPH02503919A (en) 1990-11-15
EP0359783A4 (en) 1990-06-27
DE3854741D1 (en) 1996-01-11
CA1336954C (en) 1995-09-12
ATE130762T1 (en) 1995-12-15
DK651689A (en) 1990-02-26
EP0359783B1 (en) 1995-11-29
DE3856566T2 (en) 2004-06-24
EP0666080B1 (en) 2004-01-21
DE3854741T3 (en) 2002-08-14
ATE258065T1 (en) 2004-02-15
AU2079788A (en) 1989-01-19
JP2512796B2 (en) 1996-07-03
EP0359783A1 (en) 1990-03-28
DK651689D0 (en) 1989-12-20
EP0666080A1 (en) 1995-08-09
WO1988010120A1 (en) 1988-12-29
EP0359783B2 (en) 2002-04-17
AU632991B2 (en) 1993-01-21
DE3856566D1 (en) 2004-02-26
DK175666B1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
DE3854741T2 (en) TREATING AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS.
ATE319474T1 (en) TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS
PT627933E (en) BYSTANDER OF AUTOMATIC DISEASES
ATE157257T1 (en) ENHANCEMENT OF SUPPRESSIVE REGULATION OF AUTOIMMUNE DISEASES BY ORAL OR ENTERAL ADMINISTRATION OF AUTOANTIGENS
DK0430474T3 (en) Sustained-release preparations for the treatment of periodontal disease
DE69033487T2 (en) TREATING AUTOIMMUNE DISEASES BY ADMINISTRATING AUTOANTIGENS IN THE FORM OF AEROSOL
ATE133859T1 (en) SUSTAINED-RELEASE PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF PERIODONTAL DISEASES
DE3786893D1 (en) PIPERIDE DERIVATIVE FOR THE TREATMENT OF PAIN.
SE7902742L (en) DISUBSTITUTED 3-CEFEM-4-CARBOXYLIC ACID DERIVATIVES AND PROCEDURES FOR THE PREPARATION
IT8721115A0 (en) PHYTO-PREPARATION FOR THE TREATMENT OF SKIN DISEASES.
DE3687233T2 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING SKIN DISEASES.
ATE65394T1 (en) TREATMENT OF BONE DISEASE.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: AUTOIMMUNE, INC., PASADENA, CALIF., US